source
- OmicsBank secures $2.25M to expand overseas patient data platform for biopharmaOmicsBank announced it has closed a $2.25 million financing round aimed at scaling its platform that aggregates patient health data from overseas sources for use by biopharma companies. The compan…
- Curium seeks FDA review of rival radioligand therapy to boost supply resilience against Novartis' PluvictoCurium is preparing to challenge Novartis' dominant prostate cancer radioligand therapy, Pluvicto, by entering discussions with the FDA about reviewing its own PSMA‑directed Lu‑177 candidate. Nova…